Fasiha Kanwal1,2,3, Saira Khaderi1, Amit G Singal4, Jorge A Marrero4, Nicole Loo5, Sumeet K Asrani6, Christopher I Amos7, Aaron P Thrift7, Xiangjun Gu7, Michelle Luster1, Abeer Al-Sarraj1,2,3, Jing Ning8, Hashem B El-Serag1,2,3. 1. Sections of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA. 2. Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. 3. VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA. 4. Division of Digestive and Liver Diseases, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA. 5. Texas Liver Institute, San Antonio, Texas, USA. 6. Baylor University Medical Center, Dallas, Texas, USA. 7. Section of Epidemiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. 8. Department of Biostatistics, UT MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
BACKGROUND AND AIMS: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk. APPROACH AND RESULTS: We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person-years of follow-up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51-2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2-fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24-3.35). Current smoking (HR, 1.63; 95% CI, 1.01-2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08-2.95) were also associated with HCC risk. CONCLUSIONS: HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.
BACKGROUND AND AIMS: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk. APPROACH AND RESULTS: We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person-years of follow-up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51-2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2-fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24-3.35). Current smoking (HR, 1.63; 95% CI, 1.01-2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08-2.95) were also associated with HCC risk. CONCLUSIONS: HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.
Authors: Fasiha Kanwal; Jennifer R Kramer; Steven M Asch; Yumei Cao; Liang Li; Hashem B El-Serag Journal: Hepatology Date: 2019-08-19 Impact factor: 17.425
Authors: Darrick K Li; Yanjie Ren; Daniel S Fierer; Stephanie Rutledge; Obaid S Shaikh; Vincent Lo Re; Tracey Simon; Abdul-Badi Abou-Samra; Raymond T Chung; Adeel A Butt Journal: Hepatology Date: 2018-04-19 Impact factor: 17.425
Authors: Sahil Mittal; Jennifer R Kramer; Ronald Omino; Maneerat Chayanupatkul; Peter A Richardson; Hashem B El-Serag; Fasiha Kanwal Journal: Clin Gastroenterol Hepatol Date: 2017-09-01 Impact factor: 11.382
Authors: Jessica L Petrick; Peter T Campbell; Jill Koshiol; Jake E Thistle; Gabriella Andreotti; Laura E Beane-Freeman; Julie E Buring; Andrew T Chan; Dawn Q Chong; Michele M Doody; Susan M Gapstur; John Michael Gaziano; Edward Giovannucci; Barry I Graubard; I-Min Lee; Linda M Liao; Martha S Linet; Julie R Palmer; Jenny N Poynter; Mark P Purdue; Kim Robien; Lynn Rosenberg; Catherine Schairer; Howard D Sesso; Rashmi Sinha; Meir J Stampfer; Marcia Stefanick; Jean Wactawski-Wende; Xuehong Zhang; Anne Zeleniuch-Jacquotte; Neal D Freedman; Katherine A McGlynn Journal: Br J Cancer Date: 2018-03-09 Impact factor: 7.640
Authors: Hyun-Seok Kim; Xiangjun Xiao; Jinyoung Byun; Goo Jun; Stacia M DeSantis; Han Chen; Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal; Christopher I Amos Journal: JAMA Netw Open Date: 2022-10-03